; and (ii) such testing (and the results of such testing) shall not affect the individual's access to care or public assistance and shall not be the sole factor in a family separation determination involving the individual; and (D) shall ensure that any health care provider involved in the delivery or care of an infant identified as being affected by substance abuse or withdrawal symptoms resulting from prenatal drug exposure, or a Fetal Alcohol Spectrum Disorder, is not required to notify the child protective services system of the State or any unit of local government of the State of the occurrence of such condition in such infant if such condition is the result of the birthing parent of the infant taking a prescription drug, including a prescription drug for the treatment of a substance use disorder, in accordance with the recommendations of the prescribing practitioner, and such provider has no other reason to suspect that the infant is in imminent danger of abuse or neglect. (2) Definition of prescription drug In this subsection, the term prescription drug means a drug approved under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) or licensed under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ) that is subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 353(b)(1) ). . (b) Effective date The amendment made by this section shall take effect on the date that is 2 years after the date of enactment of this Act. 3. Ensuring a whole-of-government approach through a Federal interagency task force to support families impacted by substance use disorders (a) Establishment There is established within the Federal Government an interagency task force to improve— (1) efforts, resources, and services of the Federal Government to support families impacted by substance use disorders; (2) the utilization of such efforts, resources, and services